Adjudicated US Private
Outcome Health: $1B Deceptive Pharmaceutical Advertising Analytics and Screen Count Fraud
Sold pharmaceutical advertising inventory on doctor waiting room screens that did not exist, inflating delivery metrics to fraudulently raise $1B from investors including Google and Goldman Sachs.
CASE PROFILE & BENCHMARKS
- Target Issuer: Outcome Health LLC (US).
- Fraud Period: January 1, 2017 to December 31, 2019.
- Reported Overstatement: $1.0B.
- Total Fines & Penalties: $70.0M.
- Maximum Incarceration: No prison sentence.
- Independent Auditor: KPMG LLP.
- Primary Schemes: fictitious revenue.
- Enforcement Status: ADJUDICATED (admitted).
OVERSTATEMENT $1.0B USD reported
TOTAL PENALTIES $70.0M Civil & disgorgement
PRISON TIME None No prison sentence
FIRST ACTION September 20, 2019 Initial proceeding
DETECTION METHOD Regulatory Enforcement & Forensic Audit Discovery source
PRIMARY REGULATOR U.S. Securities and Exchange Commission US
FORENSIC ACCOUNTING AUTOPSY & MECHANICS
HOW IT WAS DONE| Forensic Aspect | Regulatory Record & Ledger Mechanics |
|---|---|
| Accounting Mechanics | In settled proceedings with admissions, the regulator found that The company manipulated its accounting records by executing schemes under fictitious-revenue. Financial reports filed with market regulators contained material misstatements that distorted true financial condition. |
| Evidentiary Finding | Sold pharmaceutical advertising inventory on doctor waiting room screens that did not exist, inflating delivery metrics to fraudulently raise $1B from investors including Google and Goldman Sachs. |
| Mechanism Definition | Fabricating entirely nonexistent sales transactions, fake customers, forged purchase orders, or forged shipping manifests. |
| Affected Accounts | Accounts Receivable (Asset) • Sales Revenue (Income Statement) • Cash (fabricated through circular banking) |
| Issuer Corporate Context | Healthcare advertising startup whose founders were criminally convicted of wire fraud for selling nonexistent advertising screens and fabricating ad metrics. |
| Independent Auditor | KPMG LLP : Big Four accounting network penalized for audit failures in Carillion, Xerox, and the PCAOB inspection leak scandal. |
| Primary Discovery Method | Regulatory Enforcement & Forensic Audit |
ILLUSTRATIVE GENERAL LEDGER MECHANICS (FICTITIOUS REVENUE)
IMPROPER VS. GAAP/IFRS TREATMENT| Improper Booked Entry | Proper GAAP / IFRS Treatment | Accounting Distortion & Mechanism |
|---|---|---|
| DR: Accounts Receivable (Fake Customer LLC): $25,000,000 CR: Commercial Revenue: $25,000,000 | DR: No entry (transaction never occurred) CR: No entry | Employees manufacture fake sales orders, generate bogus invoices, and send verification confirmations to accomplice mailing addresses or shell entities. |
FINANCIAL STATEMENT & RATIO DISTORTIONS
QUANTITATIVE SCREENING SIGNALS| Financial Metric / Ratio | Distortion Direction | Forensic Explanation |
|---|---|---|
| Days Sales Outstanding (DSO) | Explodes upward | Fabricated invoices cannot be collected through normal commercial means. |
| Taxonomy | Applicable Scheme Classifications |
|---|---|
| Correlated Schemes |
CHARGED RESPONDENTS & OUTCOMES
1 NAMED PARTIES| Respondent | Role | Disposition & Judicial Outcome | Prison | Civil Penalty | O&D Bar |
|---|---|---|---|---|---|
| Outcome Health LLC | ISSUER | Enforcement order and financial sanctions imposed. | None | $70.0M | No |
RED FLAGS OBSERVED PRIOR TO DISCOVERY
1 EARLY WARNING INDICATORS| Red Flag Indicator | Period Observed | Observed Forensic Anomaly | Diagnostic View |
|---|---|---|---|
| CASH FLOW TO NET INCOME DIVERGENCE | 2017 | Operating cash flow severely diverged from reported earnings | Inspect Metric → |
ENFORCEMENT ACTIONS & PRIMARY DOCKETS
PRIMARY SOURCE CITATIONS| Filing Date | Type & Docket ID | Enforcement Order & Regulatory Findings | Disposition | Primary Record |
|---|---|---|---|---|
| September 20, 2019 | aaer ENF-2017-outcome-health | Enforcement Action: Outcome Health: $1B Deceptive Pharmaceutical Advertising Analytics and Screen Count Fraud Sold pharmaceutical advertising inventory on doctor waiting room screens that did not exist, inflating delivery metrics to fraudulently raise $1B from investors including Google and Goldman Sachs. Exchange Act § 10(b) / Rule 10b-5
Source: U.S. Securities and Exchange Commission: Accounting and Auditing Enforcement Releases (AAER) • Official Jurisdiction: US | admitted | Docket Record ↗ |
TIMELINE OF EVENTS
2 CHRONOLOGICAL MILESTONES| Date | Event Category | Chronological Forensic Milestone |
|---|---|---|
| June 1, 2017 | MISSTATEMENT | Material accounting irregularities commenced. |
| September 20, 2019 | ENFORCEMENT | Regulators commenced formal proceedings. |